FDA Approves Idvynso: Two-Drug Once-Daily Tablet

What Is Idvynso and How Does It Treat HIV?

Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) already marketed by Merck under the brand name Pifeltro and as part of the three-drug combination Delstrigo. It binds to the HIV reverse transcriptase enzyme, blocking the virus from converting its RNA into DNA and halting replication. Doravirine has been shown in pivotal trials such as DRIVE-FORWARD and DRIVE-AHEAD to deliver durable viral suppression with a favorable lipid and central nervous system tolerability profile.

Islatravir represents a newer mechanism: it is a nucleoside reverse transcriptase translocation inhibitor (NRTTI), the first agent in this class to reach the market. By incorporating into viral DNA and preventing translocation along the template strand, islatravir disrupts replication at a different step than traditional NRTIs. The high intracellular potency of islatravir allows it to be combined at low doses, which is central to the rationale for a simplified two-drug regimen rather than the historic three-drug standard.

Why Does a Two-Drug Switch Therapy Matter for People Living With HIV?

For decades, the cornerstone of antiretroviral therapy has been triple-drug combinations, typically built around two nucleoside backbone drugs plus an integrase inhibitor, NNRTI, or boosted protease inhibitor. While extraordinarily effective, this approach exposes patients to lifelong polypharmacy. As people with HIV now routinely live into older age, clinicians and guideline bodies including the U.S. Department of Health and Human Services and the International Antiviral Society-USA have increasingly endorsed two-drug maintenance regimens for selected patients to minimize cumulative metabolic, renal, and bone effects.

Idvynso joins a small but growing class of two-drug fixed-dose tablets, alongside dolutegravir/lamivudine (Dovato) and dolutegravir/rilpivirine (Juluca). Its approval is positioned as a switch option, meaning it is intended for adults who are already on a stable antiretroviral regimen with an undetectable viral load and no history of treatment failure or known resistance to either component. By offering an alternative mechanism profile that does not rely on integrase inhibitors or tenofovir-based backbones, Idvynso expands the toolkit for individualizing long-term HIV care.

What Is the Clinical and Public Health Significance of This Approval?

According to UNAIDS, an estimated 39 million people worldwide are living with HIV, and the World Health Organization reports that more than 30 million are receiving antiretroviral therapy. In the United States, the Centers for Disease Control and Prevention estimate that around 1.2 million people are living with HIV. For these patients, modern therapy can suppress the virus to undetectable levels, preventing progression to AIDS and eliminating sexual transmission, a principle known as Undetectable equals Untransmittable (U=U).

The arrival of additional once-daily, low-pill-burden regimens like Idvynso supports adherence, which is the most important predictor of long-term outcomes. It also complements parallel innovations in long-acting injectable therapy and pre-exposure prophylaxis, including agents such as cabotegravir and lenacapavir. While such advances mark significant clinical progress, public health experts emphasize that closing gaps in testing, linkage to care, and global access remains essential to meeting UNAIDS targets aimed at ending the HIV epidemic as a public health threat.